SAREPTA THERAPEUTICS, INC. Proceeds from Convertible Debt
SAREPTA THERAPEUTICS, INC. (SRPT) reported Proceeds from Convertible Debt of $570.00 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-26.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2020-02-26
- SAREPTA THERAPEUTICS, INC. proceeds from convertible debt for the quarter ending 2012-09-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. proceeds from convertible debt for the quarter ending 2012-06-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. proceeds from convertible debt for the quarter ending 2012-03-31 was $0.00.
- SAREPTA THERAPEUTICS, INC. proceeds from convertible debt for the quarter ending 2011-09-30 was $0.00.
- SAREPTA THERAPEUTICS, INC. proceeds from convertible debt for fiscal 2017 was $570.00M.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month | Proceeds from Convertible Debt 371 month | Proceeds from Convertible Debt 374 month | Proceeds from Convertible Debt 377 month | Proceeds from Convertible Debt 380 month | Proceeds from Convertible Debt 383 month | Proceeds from Convertible Debt 386 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | $570.00M 10-K · filed 2020-02-26 | |||||||||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $0.00 derived: sum of 2 quarters · filed 2012-11-07 | $0.00 10-Q · filed 2012-11-07 | $80.00K 10-Q · filed 2012-11-07 | ||||||
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $0.00 10-Q · filed 2012-08-07 | $80.00K 10-Q · filed 2012-08-07 | |||||||
| 2012-03-31 | $0.00 10-Q · filed 2012-05-10 | $80.00K 10-Q · filed 2012-05-10 | ||||||||
| 2011-12-31 | $80.00K 10-K · filed 2012-03-13 | |||||||||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $0.00 derived: sum of 2 quarters · filed 2012-11-07 | $0.00 10-Q · filed 2012-11-07 | $80.00K 10-Q · filed 2011-11-08 | ||||||
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $0.00 10-Q · filed 2012-08-07 | $80.00K 10-Q · filed 2011-08-08 | |||||||
| 2011-03-31 | $0.00 10-Q · filed 2012-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |